Company: BIAF
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010787
Chunk: 42

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 42
---
 expenses and other assets 
     6,446  
     (23,883)
  
    Accounts payable 
     394,267  
     (220,796)
  
    Accrued expenses 
     (27,987) 
     (266,492)
  
    Unearned revenue 
     —  
     (2,884)
  
    Operating lease right-of-use asset 
     426  
     (516)
  
    Net cash used in operating activities 
     (1,641,775) 
     (2,345,975)

    Cash flows from investing activities 

    Purchase of property and equipment 
     (50,786) 
     (41,387)
  
    Net cash used in investing activities 
     (50,786) 
     (41,387)

    Cash flows from financing activities 

    Proceeds from issuance of Common Stock from direct offering, net of underwriting discounts, commissions, and offering expenses of $495,000 in 2024 
     —  
     2,005,000 
  
    Proceeds from exercised stock options 
     —  
     74,899 
  
    Proceeds from exercise of warrants, net of underwriting discounts, commissions, and offering expenses of $243,145 
     1,171,169  
     — 
  
    Payment on loans payable 
     (38,927) 
     — 
  
    Proceeds from loans payable 
     —  
     27,723 
  
    Principal repayments on finance leases 
     (100,266) 
     (88,665)
  
    Net cash provided by financing activities 
     1,031,976  
     2,018,957 

    Net decrease in cash and cash equivalents 
     (660,585) 
     (368,405)
  
    Cash and cash equivalents at beginning of period 
     1,105,291  
     2,821,570 
  
    Cash and cash equivalents at end of period 
    $444,706  
    $2,453,165 

    Supplemental disclosures of cash flow information: 

    Interest expense paid in cash 
    $542  
    $23,550 
  
    Income taxes paid in cash 
     8,695  
     3,672 

The